Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Fractionated gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) based induction chemotherapy is safe and highly effective for newly diagnosed favorable risk AML.

Brenda Castillo, Jacob Appelbaum, Megan Othus, Katie Russell, Rutu Vyas, Paul Hendrie, Anna Halpern, Cristina Maria Ghiuzeli, Ryan Cassaday, Raya Mawad, Mary-Elizabeth Percival, Roland Walter

Blood (2025) 146 (Supplement 1): 3378.

https://doi.org/10.1182/blood-2025-3378

Published: 2025

Journal Articles

KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)

Jessica Leonard, Abdullah Ladha, Rawan Faramand, Gregory Roloff, Yannis Valtis, Virginia Tan, Katharine Miller, Amy Zhang, Michael Grunwald, Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali Al-Darobi, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Sumithira Vasu, Evandro Bezerra, Kristen O'Dwyer, Jozal Moore, Eunice Wang, Ross McCauley, Navneet Majhail, Aravind Ramakrishnan, Luke Mountjoy, Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Hrishikesh Srinagesh, Katherine Sutherland, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Caspian Oliai, Georgia Lill, Wendy Stock, Marc Schwartz, Tamer Othman, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Veronika Bachanova, Sean Tracy, Punita Grover, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Noelle Frey, Lori Muffly, Bijal Shah, Ibrahim Aldoss

Blood (2025) 146 (Supplement 1): 3365.

https://doi.org/10.1182/blood-2025-3365

Published: 2025

Journal Articles

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel

Ross McCauley, Amy Zhang, Vamsi Kota, Jacob Boccucci, Michael Grunwald, Matthew Ulrickson, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Ibrahim Aldoss, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Silvina Odstrcil Bobillo, Stephanie Tsai, Talal Hilal, Bijal Shah, Rawan Faramand, Jae Park, Yannis Valtis, Tamer Othman, Sumithira Vasu, Evandro Bezerra, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Wendy Stock, Caspian Oliai, Georgia Lill, Marc Schwartz, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Ali Al-Darobi, Evan Chen, Catherine Lee, Timothy O'Connor, Bhagirathbhai Dholaria, Veronika Bachanova, Sean Tracy, Hrishikesh Srinagesh, Katharine Miller, Katherine Sutherland, Navneet Majhail, Luke Mountjoy, Shahbaz Malik, Aravind Ramakrishnan, Paul Shaughnessy, John Mathews, Eunice Wang, Minoo Battiwalla, Gregory Roloff, Lori Muffly

Blood (2025) 146 (Supplement 1): 2396.

https://doi.org/10.1182/blood-2025-2396

Published: 2025

Journal Articles

Evaluation of CAR-T access barriers in Washington and Alaska: A single-center experience prior to implementing program capacity expansion

Melinda Biernacki, Agie Cole, Kausar Abukar, Isatou Barrow, Lorenzo Iovino, Natalie Wuliji, Mohamed Sorror, Erik Kimble, Edus Warren, Ryan Cassaday, Jordan Gauthier, Meredith Durbin, Alexandre Hirayama, Brian Till, Aude Chapuis, Filippo Milano, Lawrence Fong, Mazyar Shadman, Folashade Otegbeye

Blood (2025) 146 (Supplement 1): 6202.

https://doi.org/10.1182/blood-2025-6202

Published: 2025

Journal Articles

A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)

Blood (2025) 146 (Supplement 1): 5954.

https://doi.org/10.1182/blood-2025-5954

Published: 2025

Journal Articles

Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis

Blood (2025) 146 (Supplement 1): 2715.

https://doi.org/10.1182/blood-2025-2715

Published: 2025

Journal Articles

Pivekimab sunirinine (PVEK) combined with FLAG-IDA for medically fit adults with untreated adverse-risk Acute Myeloid Leukemia (AML) or other high-grade myeloid neoplasms (NCT06034470)

Jacob Appelbaum, Suravi Raychaudhuri, Katie Russell, Kimberly Cadiz, Stacey Fuller, Anna Halpern, Cristina Maria Ghiuzeli, Raya Mawad, Vivian Oehler, Ryan Cassaday, Jason Cooper, Paul Hendrie, Megan Othus, Mary-Elizabeth Percival, Roland Walter

Blood (2025) 146 (Supplement 1): 3422.

https://doi.org/10.1182/blood-2025-3422

Published: 2025

Journal Articles

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

Blood (2025) 146 (Supplement 1): 928.

https://doi.org/10.1182/blood-2025-928

Published: 2025

Journal Articles

Clinical features and outcomes of acquired versus baseline TP53 mutations in myeloid neoplasms: A single-center retrospective analysis

Jason Gilbert, Megan Othus, Suravi Raychaudhuri, Katie Russell, Carole Shaw, Rutu Vyas, Anna Halpern, Paul Hendrie, Raya Mawad, Cristina Maria Ghiuzeli, Ryan Cassaday, Roland Walter, Jacob Appelbaum, Mary-Elizabeth Percival

Blood (2025) 146 (Supplement 1): 7022.

https://doi.org/10.1182/blood-2025-7022

Published: 2025

Journal Articles

Treatment intensity and transplant independently predict survival in TP53-mutated myeloid neoplasms: A large retrospective cohort study of clinical and genomic factors

Sarah Peterson, Megan Othus, Katie Russell, Carole Shaw, Rutu Vyas, Anna Halpern, Cristina Maria Ghiuzeli, Paul Hendrie, Ryan Cassaday, Raya Mawad, Roland Walter, Jacob Appelbaum, Mary-Elizabeth Percival

Blood (2025) 146 (Supplement 1): 5265.

https://doi.org/10.1182/blood-2025-5265

Published: 2025

Journal Articles

Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world

Aaron Logan, Fevzi Yalniz, Amy Zhang, Katharine Miller, Katherine Sutherland, Nikeshan Jeyakumar, Hrishikesh Srinagesh, Michael Grunwald, Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali Al-Darobi, Joshua Sasine, LaQuisa Hill, Ibrahim Muhsen, Anjali Advani, Ibrahim Aldoss, Tamer Othman, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Yannis Valtis, Sumithira Vasu, Evandro Bezerra, Eunice Wang, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Ross McCauley, Navneet Majhail, Luke Mountjoy, Aravind Ramakrishnan, Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Wendy Stock, Gregory Roloff, Caspian Oliai, Georgia Lill, Marc Schwartz, Divya Koura, Kaitlyn Dykes, Michael Daunov, Ken Byrd, Veronika Bachanova, Sean Tracy, Punita Grover, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Rawan Faramand, Lori Muffly

Blood (2025) 146 (Supplement 1): 516.

https://doi.org/10.1182/blood-2025-516

Published: 2025

Journal Articles

Concurrent use of nucleoside reverse transcriptase inhibitors and purine analogs is associated with worse survival for patients with myeloid neoplasms: A single-center retrospective analysis

Blood (2025) 146 (Supplement 1): 1677.

https://doi.org/10.1182/blood-2025-1677

Published: 2025

Journal Articles

A randomized phase 2 trial of CPX-351 vs. CLAG-m (Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone) in medically less-fit adults with previously untreated acute myeloid leukemia (AML) or other high-grade myeloid neoplasms

Anna Halpern, Megan Othus, Mary-Elizabeth Percival, Cristina Maria Ghiuzeli, Jacob Appelbaum, Paul Hendrie, Ryan Cassaday, Bart Scott, Jason Cooper, Sioban Keel, Vivian Oehler, Johnnie Orozco, Katie Russell, Raya Mawad, Roland Walter

Blood (2025) 146 (Supplement 1): 1663.

https://doi.org/10.1182/blood-2025-1663

Published: 2025

Journal Articles

Lack of efficacy of levocarnitine for the treatment of pegylated asparaginase-related hepatotoxicity during induction or salvage chemotherapy in adults with acute lymphoblastic leukemia: A comparative, retrospective, University of California hematologic malignancies consortium (UCHMC) study

Logan Deyo, Alyssa Guo, Scott Isom, Daria Gaut, Caspian Oliai, Bennett Caughey, Richard Fong, Lloyd Damon, Kevin Shieh, An To, Benjamin Lee, Deepa Jeyakumar, Brian Jonas, Ryan Cassaday, Matthew Wieduwilt

Blood (2025) 146 (Supplement 1): 3328.

https://doi.org/10.1182/blood-2025-3328

Published: 2025

Journal Articles

Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) yields durable remissions and survival in adults with newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL): Long-term follow-up of a prospective trial

Mitin Nachu, Philip Stevenson, Kim Quach, Christen Martino, Mary-Elizabeth Percival, Anna Halpern, Pamela Becker, Vivian Oehler, Jason P. Cooper, Johnnie Orozco, Paul Hendrie, Roland Walter, Cristina Maria Ghiuzeli, Raya Mawad, Ryan Cassaday

Blood (2025) 146 (Supplement 1): 5128.

https://doi.org/10.1182/blood-2025-5128

Published: 2025

Journal Articles

Retrospective Analysis of Adolescent Young Adult Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated with the CALGB 10403 Regimen Since Completion of Trial Enrollment

Brandon DaSilva, Rutu D. Vyas, Alicia Darwin, Kathryn Russel, Jason Gilbert, Virginia Tan, Himani Darji, Katharine Miller, Emily C Liang, Suravi Raychaudhuri, Adam S. Duvall, Michaela Liedtke, Wendy Stock, Ryan Cassaday, Marc Schwartz, Jessica T. Leonard, Marlise R. Luskin, Lori S. Muffly

Blood (2023) 142 (Supplement 1): 4240.

https://doi.org/10.1182/blood-2023-185176

Published: 2023

Journal Articles

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

Blood (2014) 124 (15): 2354–2361.

https://doi.org/10.1182/blood-2014-05-578963

Published: 2014

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Fractionated gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) based induction chemotherapy is safe and highly effective for newly diagnosed favorable risk AML.

KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel

Evaluation of CAR-T access barriers in Washington and Alaska: A single-center experience prior to implementing program capacity expansion

A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)

Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis

Pivekimab sunirinine (PVEK) combined with FLAG-IDA for medically fit adults with untreated adverse-risk Acute Myeloid Leukemia (AML) or other high-grade myeloid neoplasms (NCT06034470)

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

Clinical features and outcomes of acquired versus baseline TP53 mutations in myeloid neoplasms: A single-center retrospective analysis

Treatment intensity and transplant independently predict survival in TP53-mutated myeloid neoplasms: A large retrospective cohort study of clinical and genomic factors

Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world

Concurrent use of nucleoside reverse transcriptase inhibitors and purine analogs is associated with worse survival for patients with myeloid neoplasms: A single-center retrospective analysis

A randomized phase 2 trial of CPX-351 vs. CLAG-m (Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone) in medically less-fit adults with previously untreated acute myeloid leukemia (AML) or other high-grade myeloid neoplasms

Lack of efficacy of levocarnitine for the treatment of pegylated asparaginase-related hepatotoxicity during induction or salvage chemotherapy in adults with acute lymphoblastic leukemia: A comparative, retrospective, University of California hematologic malignancies consortium (UCHMC) study

Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) yields durable remissions and survival in adults with newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL): Long-term follow-up of a prospective trial

Retrospective Analysis of Adolescent Young Adult Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated with the CALGB 10403 Regimen Since Completion of Trial Enrollment

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only